Advertisement

Annals of Surgical Oncology

, Volume 21, Issue 5, pp 1739–1748 | Cite as

Is Preoperative Chemotherapy Followed by Surgery the Appropriate Treatment for Signet Ring Cell Containing Adenocarcinomas of the Esophagogastric Junction and Stomach?

  • Ulrike Heger
  • Susanne Blank
  • Christiane Wiecha
  • Rupert Langer
  • Wilko Weichert
  • Florian Lordick
  • Thomas Bruckner
  • Martin Dobritz
  • Maria Burian
  • Christoph Springfeld
  • Lars Grenacher
  • Jörg-Rüdiger Siewert
  • Markus Büchler
  • Katja OttEmail author
Thoracic Oncology

Background

Recent data suggest primary resection as the preferable approach in patients with signet ring cell gastric cancer (SRC). The aim of our retrospective exploratory study was to evaluate the influence of SRC on prognosis and response in esophagogastric adenocarcinoma treated with neoadjuvant chemotherapy.

Methods

A total of 723 locally advanced esophagogastric adenocarcinomas (cT3/4 N any) documented in a prospective database from two academic centers were classified according to the WHO definition for SRC (more than 50 % SRC) and analyzed for their association with response and prognosis after neoadjuvant treatment.

Results

A total of 235 tumors (32.5 %) contained SRC. Median survival of SRC was 26.3 compared with 46.6 months (p < 0.001) for non-SRC. SRC were significantly associated with female gender, gastric localization, advanced ypT and R1/2 categories, and lower risk of surgical complications and anastomotic leakage (each p < 0.001). Clinical (21.1 vs. 33.7 %, p = 0.001) and histopathological response (less than 10 % residual tumor: 16.3 vs. 28.9 %, p < 0.001) were significantly less frequent in SRC. Clinical response (p = 0.003) and complete histopathological response (pCR) (3.4 %) (p = 0.003) were associated with improved prognosis in SRC. Clinical response, surgical complications, ypTN categories, but not SRC were independent prognostic factors in forward Cox regression analysis in R0 resected patients. Risk of peritoneal carcinomatosis was increased (p < 0.001), while local (p = 0.015) and distant metastases (p = 0.02) were less frequent than in non-SRC.

Conclusions

Prognosis of SRC is unfavorable. Although response to neoadjuvant chemotherapy is rare in SRC, it is associated with improved outcome. Thus, chemotherapy might not generally be abandoned in SRC. A stratification based on SRC should be included in clinical trials.

Keywords

Gastric Cancer Peritoneal Carcinomatosis Signet Ring Cell Circumferential Resection Margin Signet Ring Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

We thank Catherine Bernaciak PhD for revising the manuscript.

References

  1. 1.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.PubMedCrossRefGoogle Scholar
  3. 3.
    Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210–8.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.PubMedCrossRefGoogle Scholar
  5. 5.
    van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.PubMedCrossRefGoogle Scholar
  6. 6.
    Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229:303–8.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21:4604–10.PubMedCrossRefGoogle Scholar
  8. 8.
    Becker K, Reim D, Novotny A, Zum Büschenfelde CM, Engel J, et al. Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg. 2012;256:1002–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Blank S, Blaker H, Schaible A, Lordick F, Grenacher L, Buechler M, et al. Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. Langenbecks Arch Surg. 2012;397:45–55.PubMedCrossRefGoogle Scholar
  10. 10.
    Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, et al. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18:2688–98.PubMedCrossRefGoogle Scholar
  11. 11.
    Reim D, Gertler R, Novotny A, Becker K, zum Büschenfelde CM, Ebert M, et al. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol. 2012;19:2108–18.PubMedCrossRefGoogle Scholar
  12. 12.
    Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev. 2009;18:1945–52.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250:878–87.PubMedCrossRefGoogle Scholar
  14. 14.
    Li C, Kim S, Lai JF, Hyung WJ, Choi WH, Choi SH, et al. Advanced gastric carcinoma with signet ring cell histology. Oncology. 2007;72:64–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg. 2011;254:684–93; discussion 693.PubMedCrossRefGoogle Scholar
  16. 16.
    Rougier P, Mahjoubi M, Lasser P, Ducreux M, Oliveira J, Ychou M, et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma—a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer. 1994;30A:1269–75.PubMedCrossRefGoogle Scholar
  17. 17.
    Takiuchi H, Hirata I, Kawabe S, Egashira Y, Katsu K. Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep. 2000;7:841–6.PubMedGoogle Scholar
  18. 18.
    Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMedGoogle Scholar
  19. 19.
    Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253:934–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol. 2012;19:2119–27.PubMedCrossRefGoogle Scholar
  21. 21.
    Lorenzen S, Panzram B, Rosenberg R, Nekarda H, Becker K, Schenk U, et al. Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection. Ann Surg Oncol. 2010;17:2733–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, et al. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol. 2011;18:3316–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14:2012–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521–30.PubMedCrossRefGoogle Scholar
  25. 25.
    Bader FG, Lordick F, Fink U, Becker K, Hofler H, Busch R, et al. Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up. Onkologie. 2008;31:366–72.PubMedCrossRefGoogle Scholar
  26. 26.
    Fink U, Schuhmacher C, Stein HJ, Busch R, Feussner H, Dittler HJ, et al. Preoperative chemotherapy for stage III–IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg. 1995;82:1248–52.PubMedCrossRefGoogle Scholar
  27. 27.
    Schuhmacher CP, Fink U, Becker K, Busch R, Dittler HJ, Mueller J, et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer. 2001;91:918–27.PubMedCrossRefGoogle Scholar
  28. 28.
    Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 2001;234:360–7; discussion 368–9.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Wang SY, Yeh CN, Lee HL, Liu YY, Chao TC, Hwang TL, et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol. 2009;16:2738–43.PubMedCrossRefGoogle Scholar
  30. 30.
    Chan DS, Reid TD, Howell I, Lewis WG. Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer. Br J Surg. 2013;100:456–64.PubMedCrossRefGoogle Scholar
  31. 31.
    Raziee HR, Cardoso R, Seevaratnam R, Mahar A, Helyer L, Law C, et al. Systematic review of the predictors of positive margins in gastric cancer surgery and the effect on survival. Gastric Cancer. 2012;15 Suppl 1:S116–24.PubMedCrossRefGoogle Scholar
  32. 32.
    Chirieac LR, Swisher SG, Correa AM, Ajani JA, Komaki RR, Rashid A, et al. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res. 2005;11:2229–36.PubMedCrossRefGoogle Scholar
  33. 33.
    van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg. 2008;8:21.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, et al. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10% residual tumor. Langenbecks Arch Surg. 2013;398:239–49.PubMedCrossRefGoogle Scholar
  35. 35.
    Homann N, Pauligk C, Luley K, Werner Kraus T, Bruch HP, Atmaca A, et al. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer. 2012;130:1706–13.PubMedCrossRefGoogle Scholar
  36. 36.
    Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, et al. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010;116:1656–63.PubMedCrossRefGoogle Scholar
  37. 37.
    Lordick F, Ott K, Weitz J, Jager D. The evolving role of catumaxomab in gastric cancer. Expert Opin Biol Ther. 2008;8:1407–15.PubMedCrossRefGoogle Scholar
  38. 38.
    Sujendran V, Wheeler J, Baron R, Warren BF, Maynard N. Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer. Br J Surg. 2008;95:191–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Jass JR, Sobin LH, Watanabe H. The World Health Organization’s histologic classification of gastrointestinal tumors. A commentary on the second edition. Cancer. 1990;66:2162–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Piessen G, Amielh D, Messager M, Vinatier E, Leteurtre E, Triboulet JP, et al. Is pretreatment endoscopic biopsy a good predictor of signet ring cell histology in gastric carcinoma? World J Surg. 2012;36:346–54.PubMedCrossRefGoogle Scholar
  41. 41.
    Flucke U, Monig SP, Baldus SE, Zirbes TK, Bollschweiler E, Thiele J, et al. Differences between biopsy- or specimen-related Lauren and World Health Organization classification in gastric cancer. World J Surg. 2002;26:137–40.PubMedCrossRefGoogle Scholar
  42. 42.
    Dikken JL, Coit DG, Klimstra DS, Rizk NP, van Grieken N, Ilson D, et al. Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma: relevance of the seventh edition American Joint Committee on Cancer Staging Manual revision. Cancer. 2012;118:349–57.PubMedCrossRefGoogle Scholar
  43. 43.
    Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248:902–8. PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Ulrike Heger
    • 1
  • Susanne Blank
    • 1
  • Christiane Wiecha
    • 1
  • Rupert Langer
    • 2
  • Wilko Weichert
    • 3
  • Florian Lordick
    • 4
  • Thomas Bruckner
    • 5
  • Martin Dobritz
    • 6
  • Maria Burian
    • 1
  • Christoph Springfeld
    • 7
  • Lars Grenacher
    • 8
  • Jörg-Rüdiger Siewert
    • 9
  • Markus Büchler
    • 1
  • Katja Ott
    • 1
    Email author
  1. 1.Department of SurgeryHeidelberg University Hospital, University of HeidelbergHeidelbergGermany
  2. 2.Department of PathologyUniversity of BernBernSwitzerland
  3. 3.Department of PathologyHeidelberg University HospitalHeidelbergGermany
  4. 4.University Cancer Center Leipzig (UCCL)University of LeipzigLeipzigGermany
  5. 5.Data Management, Institute of Medical Biometry and StatisticsIMBIHeidelbergGermany
  6. 6.Department of RadiologyTechnische Universitaet MuenchenMunichGermany
  7. 7.Department of Medical OncologyNational Center for Tumor DiseasesHeidelbergGermany
  8. 8.Department of Diagnostic and Interventional RadiologyHeidelberg University HospitalHeidelbergGermany
  9. 9.DirectorateUniversity of FreiburgFreiburgGermany

Personalised recommendations